Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2019 07:00 ET | Source: MediWound Ltd.

MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results

Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for...
March 18, 2019 08:00 ET | Source: MediWound Ltd.

MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time

YAVNE, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
March 12, 2019 07:00 ET | Source: MediWound Ltd.

MediWound Announces Executive Leadership Changes

Chief Executive Officer Gal Cohen stepping down Available for transition and ongoing strategic process support Chief Financial & Operations Officer Sharon Malka will be appointed CEO ...
January 22, 2019 06:30 ET | Source: MediWound Ltd.

MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

Met Primary and All Secondary Endpoints with Statistically Significant Results Compared with Control Group Conference call with MediWound management and U.S. key opinion leader begins today, January...
November 13, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Reports Third Quarter 2018 Financial Results

Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid® for sulfur mustard injuries Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. ...
November 07, 2018 16:05 ET | Source: MediWound Ltd.

MediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time

YAVNE, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
September 24, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid® for Sulfur Mustard Injuries

YAVNE, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
September 05, 2018 07:00 ET | Source: MediWound Ltd.

NexoBrid® Receives Marketing Authorization from Russia's Ministry of Health

Commercial launch is expected in the first half of 2019 YAVNE, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing...
September 04, 2018 08:00 ET | Source: MediWound Ltd.

MediWound to Present at 13th Annual Wells Fargo Securities Healthcare Conference

YAVNE, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
August 07, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter 2018 Financial Results

Completion of enrollment of Phase 3 DETECT Study of NexoBrid® Strategic discussions advancing with multiple parties Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 07,...